Evidence map›Paper›PMID 40936723›Full record

ArticleFrontiers in oncology2025

The prognostic value of health-related quality of life for early molecular response in patients with chronic myeloid leukemia: analysis of the GIMEMA-SUSTRENIM trial.

Fabio Efficace, Laura Cannella, Isabella Capodanno, Rosaria Sancetta, Veronica Porcu, Monia Lunghi, Annalisa Biagi, Fausto Castagnetti, Giovanni Caocci, Thomas Baldi and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Fabio EfficaceItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Laura CannellaItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Isabella CapodannoHematology Unit, Azienda Unità Sanitaria Locale-IRCCS, Reggio Emilia, Italy.
Rosaria SancettaHematology Unit, Dell'Angelo Hospital, Venezia-Mestre, Italy.
Veronica PorcuHematology Unit, S. Eugenio Hospital, ASL Roma 2, Tor Vergata University, Rome, Italy.
Monia LunghiDivision of Hematology, Department of Translation Medicine, University of Eastern Piedmont, Novara, Italy.
Annalisa BiagiHematology Unit, Santa Maria Goretti Hospital, Latina, Italy.
Fausto CastagnettiInstitute of Hematology "Seràgnoli" IRCCS Azienda Ospedaliero-Universitaria di Bologna, Department of Medical and Surgical Sciences University of Bologna, Bologna, Italy.
Giovanni CaocciHematology Unit, Businco Hospital, Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy.
Thomas BaldiItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Roberto MarascaSection of Hematology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy.
Massimiliano BonifacioDepartment of Medicine, Azienda Ospedaliera Universitaria Integrata di Verona, Verona, Italy.
Antonella GozziniHematology Unit, AOU Careggi, University of Florence, Florence, Italy.
Bruno MartinoDivision of Hematology, Grande Ospedale Metropolitano 'Bianchi Melacrino Morelli', Reggio Calabria, Italy.
Federica SoraDipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica Sacro Cuore, Rome, Italy.
Peter E WesterweelDepartment of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, Netherlands.
Paola FaziItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Marco VignettiItalian Group for Adult Hematologic Diseases (GIMEMA), Data Center and Health Outcomes Research Unit, Rome, Italy.
Fabrizio PaneHematology Section, Department of Clinical Medicine and Surgery, University of Naples "Federico II", Naples, Italy.
Massimo BrecciaHematology, Department of Translational and Precision Medicine, Azienda Ospedaliera Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We aimed to explore the prognostic value of patient-reported health-related quality of life (HRQoL) data for the achievement of early molecular response (EMR) at 3 months in patients with chronic phase chronic myeloid leukemia (CP-CML). We analyzed HRQoL baseline data of 436 newly diagnosed patients with CML patients enrolled in the GIMEMA Sustrenim trial. HRQoL was assessed by the EORTC QLQ-30 and the QLQ-CML24 questionnaires. In the multivariate analysis, the following factors were found to be independently associated with achievement of EMR: Sokal risk (low vs intermediate risk p=0.046 and low vs high risk p<0.001), nilotinib treatment (p<0.001) and higher patient-reported role functioning (EORTC QLQ-C30) (p<0.001). Current findings suggest the importance of assessing HRQoL at diagnostic workup of patients with CML as it may provide valuable prognostic information.

Indexed as

chronic myeloid leukemia (CML)early molecular response (EMR)functioningpatient reported outcome (PRO)quality of life

Identifiers

PMID40936723
PMCPMC12420324

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.